305 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Mylan (MYL) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/227132/mylan-myl-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-227132 Aug 05, 2016 - Mylan (MYL), which is set to report second-quarter 2016 results on Aug 9, delivered a positive earnings surprise of 1.33% last quarter.
Can TransDigm (TDG) Spring a Surprise in Q3 Earnings? http://www.zacks.com/stock/news/227022/can-transdigm-tdg-spring-a-surprise-in-q3-earnings?cid=CS-ZC-FT-227022 Aug 05, 2016 - TransDigm Group Incorporated (TDG) is set to report third-quarter fiscal 2016 results, after the closing bell on Aug 9.
BioDelivery (BDSI) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226971/biodelivery-bdsi-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226971 Aug 05, 2016 - Last quarter, BioDelivery's loss was in-line with expectations. Let's see how things are shaping up for the second quarter of 2016.
Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226965/jazz-jazz-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226965 Aug 05, 2016 - Our proven model does not conclusively show that Jazz (JAZZ) is likely to beat earnings estimates this quarter.
Celldex (CLDX): What's Ahead for the Stock in Q2 Earnings? http://www.zacks.com/stock/news/226771/celldex-cldx-whats-ahead-for-the-stock-in-q2-earnings?cid=CS-ZC-FT-226771 Aug 04, 2016 - With no approved product in its portfolio, investors will remain focused on pipeline related updates from Celldex (CLDX).
Allergan (AGN) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226764/allergan-agn-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226764 Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
Repros (RPRX) Q2 Earnings: What's in Store for the Stock? http://www.zacks.com/stock/news/226752/repros-rprx-q2-earnings-whats-in-store-for-the-stock?cid=CS-ZC-FT-226752 Aug 04, 2016 - With Repros being a development-stage company, investors will remain focused on the company's pipeline and cash burn.
Kite (KITE) Q2 Earnings: What's in Store for the Stock? http://www.zacks.com/stock/news/226712/kite-kite-q2-earnings-whats-in-store-for-the-stock?cid=CS-ZC-FT-226712 Aug 04, 2016 - With Kite (KITE) being a development stage company, investor focus will remain on the company's pipeline updates and cash burn.
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat http://www.zacks.com/stock/news/225805/ariads-aria-stock-up-on-q2-earnings-revenue-beat?cid=CS-ZC-FT-225805 Jul 29, 2016 - ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise? http://www.zacks.com/stock/news/224914/ariad-aria-to-report-q2-earnings-will-the-stock-surprise?cid=CS-ZC-FT-224914 Jul 26, 2016 - Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.

Pages: 1...25262728293031

<<<Page 30